Functional Personalized Complex Combination Nano Therapy for Osteosarcoma

Osteosarcoma, the most common primary bone cancer in adolescents, remains a major challenge, with survival rates below 20% for metastatic cases and no significant therapeutic progress in over 40 years[1]. Current treatments face systemic toxicity and resistance[2]. Functional personalized therapy using drug sensitivity profiling and synergistic drug combinations, offers a promising path forward. This study explores polydopamine-stabilized nanoparticles for precision-targeted kinase inhibitor delivery, addressing OS heterogeneity and treatment gaps.